Oncology Diagnostics Panel Session

In Part 2 of our Oncology Diagnostics series, our panelist provide some ideas on how to monetize technologies in efforts to help pay for rising development costs.

Making Up for Unfavorable Reimbursement


  • Shailesh Maingi – Founder and CEO, Kineticos

Panel Members

  • Eric Mayer – CEO, EDP Biotech
  • Sandra Dunn – CEO, Phoenix Molecular
  • Brian Kelly – Global Director, Diagnostic Partnering, Thermo Fisher

Part 1 – Can Diagnostics Keep Up with Pharma

Subscribe to Kineticos to receive weekly emails containing insightful content.